Pascal Biosciences Inc.
http://www.pascalbiosciences.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Pascal Biosciences Inc.
Asia Deal Watch: Ambrx, NovoCodex Partner On Second ADC Candidate, For CD70-Positive Cancers
Deal follows 2013 pact between Ambrx and NovoCodex parent Zhejiang Medicine for HER2-positive-directed ADC. Astellas teams with Pandion on pancreatic cancer and Takeda with MD Anderson on CAR NK therapies.
Tech Transfer Roundup: Tmunity Targets Pediatric Glioma With UCSF-Discovered TCR Therapy
Bayer will collaborate with start-up Hope Medicine to develop antibody therapies targeting the PRL receptor. WARF and Sanford Burnham Prebys partner on translational research.
Tech Transfer Roundup: J&J Houses JPOD Incubator At University Of Pennsylvania
Pascal and Oblato separately license therapeutic candidates for glioblastoma multiforme, while Cabaletta emerges from UPenn with novel program for CAAR-T therapies in B-cell mediated autoimmune disease.
Tech Transfer Roundup: Neon Licenses NKI IP To Advance Cell Therapy Into Clinic
Continuing a partnership between Neon co-founder and two Netherlands Cancer Institute researchers, agreement will help autologous T-cell candidate move into Phase I. Plus Scrip's monthly roundup of tech transfer deals.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
- Vaccines
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice